medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-6-26-32medsovet-2368Research ArticleНЕВРОЛОГИЯNEUROLOGYФармакологические принципы терапии инсомнииPharmacotherapy treatment principles for insomniaОковитыйС. В.OkovityiS. V.

д.м.н., профессор

MD, Prof.

ТитовичИ. А.TitovichI. A.Санкт-Петербургский государственный химико-фармацевтический университет Минздрава РоссииРоссияSaint Petersburg State Chemical Pharmaceutical University of the Ministry of Health of RussiaRussian Federation201812042018062632Copyright © Оковитый С.В., Титович И.А., 20182018Оковитый С.В., Титович И.А.Okovityi S.V., Titovich I.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2368

Фармакотерапия инсомнии является неотъемлемой частью лечения этого клинического синдрома. Спектр препаратов, используемых при нарушениях сна, весьма обширен, причем не все они относятся к «истинным» снотворным средствам, а нередко являются представителями различных классов психотропных средств. Современные снотворные препараты при соблюдении необходимых правил позволяют получить необходимое снотворное действие, не сопровождающееся негативными изменениями структуры сна и качества последующего бодрствования. Результаты отечественных и зарубежных исследований, рекомендации ведущих профессиональных сообществ (Российского общества сомнологов  – 2016; European Sleep Research Society – 2017; American Academy of Sleep Medicine – 2017; American College of Physicians – 2016) позволяют утверждать, что нормализация сна при инсомнии, в т. ч. с использованием фармакотерапии, нейтрализует ее негативное воздействие, повышает адаптивные возможности человека и способствует предотвращению развития хронических нарушений сна с их серьезными неблагоприятными последствиями.

 

Pharmacotherapy of insomnia is an integral part of the treatment of this clinical syndrome. The range of drugs used for the treatment of sleep disorders is quite extensive, and not all of them are “true” sleeping pills”. Such pills often belong to the various classes of psychotropic medications. Advanced sleeping pills taken in compliance with the necessary rules provide the necessary sleeping effect without accompanied negative changes in the sleep structure and the quality of the subsequent waking. The domestic and foreign studies, the leading professional community guidelines (the Russian Society of Somanologists – 2016, the European Sleep Research Society – 2017, the American Academy of Sleep Medicine – 2017, the American College of Physicians – 2016) show that normalization of sleep in patients with insomnia by various methods, including pharmacotherapy, neutralizes its negative effects, improves the adaptive capacity of the individual and prevents the chronic sleep disorders with severe adverse effects.

инсомниякогнитивно-поведенческая терапияфармакотерапияснотворные средстваагонисты бензодиазепиновых рецепторовагонисты мелатониновых рецепторовантагонисты Н1-гистаминовых рецепторовдоксиламинinsomniacognitive-behavioral therapypharmacotherapysleeping agentsbenzodiazepine receptor agonistsmelatonin receptor agonistsH1-histamine receptor antagonistsdoxylamineReferencesLichstein KL, Taylor DJ, McCrae CS, Petrov ME. Insomnia: epidemiology and risk factors. Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016: 761-768.Lichstein KL, Taylor DJ, McCrae CS, Petrov ME. Insomnia: epidemiology and risk factors. Principles and Practice of Sleep Medicine. 6th ed. Philadelphia: Elsevier, 2016: 761-768.Полуэктов М.Г., Бузунов Р.В., Авербух В.М. и др. Проект клинических рекомендаций по диагностике и лечению хронической инсомнии у взрослых. Consilium medicum. Неврология, 2016, 2: 41-51.Poluekstiv MG, Buzunov RV, Averbukh VM et al. The draft of clinical guidelines for diagnosis and treatment of chronic insomnia in adults. Consilium medicum. Nevrologiya, 2016, 2: 41-51American Academy of Sleep Medicine. International classification of sleep disorders, 3 ed.: Diagnostic and coding manual. Westchester, Ill.: American Academy of Sleep Medicine, 2014.American Academy of Sleep Medicine. International classification of sleep disorders, 3 ed.: Diagnostic and coding manual. Westchester, Ill.: American Academy of Sleep Medicine, 2014.Riemann D, Nissen C, Palagini L et al. The neurobiology, investigation, and treatment of chronic insomnia. The Lancet Neurology, 2015, 14(5): 547-558.Riemann D, Nissen C, Palagini L et al. The neurobiology, investigation, and treatment of chronic insomnia. The Lancet Neurology, 2015, 14(5): 547-558.Riemann D, Baglioni C, Bassetti C et al. Euro-pean guideline for the diagnosis and treatment of insomnia. J Sleep Res, 2017, 26(6): 675-700.Riemann D, Baglioni C, Bassetti C et al. Euro-pean guideline for the diagnosis and treatment of insomnia. J Sleep Res, 2017, 26(6): 675-700.Dean GE, Weiss C, Morris JL, Chasens ER. Impaired sleep: A multifaceted geriatric syndrome. Nurs Clin N Am, 2017, 52(3): 387-404.Dean GE, Weiss C, Morris JL, Chasens ER. Impaired sleep: A multifaceted geriatric syndrome. Nurs Clin N Am, 2017, 52(3): 387-404.Mendelson WB, Roth T, Cassella J et al. The treatment of chronic insomnia: drug indications, chronic use and liability: summary of a 2001 new clinical drug evaluation unit meeting symposium. Sleep Med Rev, 2004, 8(1): 7-17.Mendelson WB, Roth T, Cassella J et al. The treatment of chronic insomnia: drug indications, chronic use and liability: summary of a 2001 new clinical drug evaluation unit meeting symposium. Sleep Med Rev, 2004, 8(1): 7-17.Левин Я.И., Ковров Г.В. Некоторые современные подходы к терапии инсомнии. Лечащий врач, 2003, 4: 18-24.Levin YaI, Kovrov GV. Modern approaches to the treatment of insomnia. Lechashchiy Vrach, 2003, 4: 18-24.Möhler H, Fritschy J M, Rudolph U. A new benzodiazepine pharmacology. Journal of Pharmacology and Experimental Therapeutics, 2002, 300(1): 2-8.Möhler H, Fritschy J M, Rudolph U. A new benzodiazepine pharmacology. Journal of Pharmacology and Experimental Therapeutics, 2002, 300(1): 2-8.Holbrook AM, Crowther R, Lotter A et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ, 2000, 162(2): 225-233.Holbrook AM, Crowther R, Lotter A et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ, 2000, 162(2): 225-233.Longo LP, Johnson B. Addiction: part I. Benzodiazepines - side effects, abuse risk, and alternatives. Am Fam Physician, 2000, 61(7): 2121-2128.Longo LP, Johnson B. Addiction: part I. Benzodiazepines - side effects, abuse risk, and alternatives. Am Fam Physician, 2000, 61(7): 2121-2128.Brasure M, MacDonald R, Fuchs E et al. Management of insomnia disorder. comparative effectiveness review No. 159.(Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2012-00016-I). AHRQ Publication No. 15 (16)-EHC027-EF. Rockville, MD: Agency for Healthcare Research and Quality, 2016.Brasure M, MacDonald R, Fuchs E et al. Management of insomnia disorder. comparative effectiveness review No. 159.(Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2012-00016-I). AHRQ Publication No. 15 (16)-EHC027-EF. Rockville, MD: Agency for Healthcare Research and Quality, 2016.Walsh JK, Krystal AD, Amato DA et al. Nightly treatment of primary insomnia with eszopi-clone for six months: effect on sleep, quality of life, and work limitations. Sleep, 2007, 30(8): 959-968.Walsh JK, Krystal AD, Amato DA et al. Nightly treatment of primary insomnia with eszopi-clone for six months: effect on sleep, quality of life, and work limitations. Sleep, 2007, 30(8): 959-968.Krystal A, Walsh J, Laska E et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep, 2003, 26(7): 793-799.Krystal A, Walsh J, Laska E et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep, 2003, 26(7): 793-799.Elie R, Ruther E, Farr I et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry, 1999, 60(8): 536-544.Elie R, Ruther E, Farr I et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry, 1999, 60(8): 536-544.Fry J, Scharf M, Mangano R et al. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Int Clin Psychopharmacol, 2000, 15(3): 141-152.Fry J, Scharf M, Mangano R et al. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Int Clin Psychopharmacol, 2000, 15(3): 141-152.Randall S, Roehrs TA, Roth T. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep, 2012, 35(11): 1551-1557.Randall S, Roehrs TA, Roth T. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep, 2012, 35(11): 1551-1557.Roth T, Krystal A, Steinberg FJ et al. Novel sub-lingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebocontrolled, outpatient study. Sleep, 2013, 36(2): 189-196.Roth T, Krystal A, Steinberg FJ et al. Novel sub-lingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebocontrolled, outpatient study. Sleep, 2013, 36(2): 189-196.Krystal AD, Erman M, Zammit GK et al. Longterm efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep, 2008, 31(1): 79-90.Krystal AD, Erman M, Zammit GK et al. Longterm efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep, 2008, 31(1): 79-90.Ancoli-Israel S, Krystal AD, McCall WV et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep, 2010, 33(2): 225-234.Ancoli-Israel S, Krystal AD, McCall WV et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep, 2010, 33(2): 225-234.Leppik I, Roth-Schechter G, Gray G et al. Double blind, placebo controlled comparison of zolpidem, triazolam, and temazepam in elderly pati ents with insomnia. Drug Dev Res, 1997, 40: 230-238.Leppik I, Roth-Schechter G, Gray G et al. Double blind, placebo controlled comparison of zolpidem, triazolam, and temazepam in elderly pati ents with insomnia. Drug Dev Res, 1997, 40: 230-238.Pillai V, Roth T, Roehrs T et al. Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: an examination of response and remission rates. Sleep, 2017, 40(2): zsw044.Pillai V, Roth T, Roehrs T et al. Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: an examination of response and remission rates. Sleep, 2017, 40(2): zsw044.Wilson SJ, Nutt DJ, Alford C et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol, 2010, 24(11): 1577-1601.Wilson SJ, Nutt DJ, Alford C et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol, 2010, 24(11): 1577-1601.Charles AC, Winkelman JW, Richardson GS. Sleep disorders. Harrison’s internal medicine. 17th ed. New York: McGraw-Hill Publishing, 2005: 153-161.Charles AC, Winkelman JW, Richardson GS. Sleep disorders. Harrison’s internal medicine. 17th ed. New York: McGraw-Hill Publishing, 2005: 153-161.Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev, 2015, 7: CD011090.Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev, 2015, 7: CD011090.Brzezinski A, Vangel MG, Wurtman RJ et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep medicine reviews, 2005, 9(1): 41-50.Brzezinski A, Vangel MG, Wurtman RJ et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep medicine reviews, 2005, 9(1): 41-50.Spadoni G, Bedini A, Lucarini S, Mor M et al. Pharmacokinetic and pharmacodynamic evaluation of ramelteon: an insomnia therapy. Expert Opin Drug Metab Toxicol, 2015, 11(7): 1145-1156.Spadoni G, Bedini A, Lucarini S, Mor M et al. Pharmacokinetic and pharmacodynamic evaluation of ramelteon: an insomnia therapy. Expert Opin Drug Metab Toxicol, 2015, 11(7): 1145-1156.Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther, 2009, 15(1): 32-51.Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther, 2009, 15(1): 32-51.Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep, 2005, 28(3): 303-307.Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep, 2005, 28(3): 303-307.Mayer G, Wang-Weigand S, Roth-Schechter B et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep, 2009, 32(3): 351-360.Mayer G, Wang-Weigand S, Roth-Schechter B et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep, 2009, 32(3): 351-360.Kato K, Hirai K, Nishiyama J et al. Neurochemical properties of ramelteon (TAK-375), as selective MT1/MT2 receptor agonist. Neuropharmacology, 2005, 48(2): 301-310.Kato K, Hirai K, Nishiyama J et al. Neurochemical properties of ramelteon (TAK-375), as selective MT1/MT2 receptor agonist. Neuropharmacology, 2005, 48(2): 301-310.Walsh JK. Drugs used to treat insomnia in 2002: regulatory based rather than evidence based medicine. Sleep, 2004, 27(8): 1441-1442.Walsh JK. Drugs used to treat insomnia in 2002: regulatory based rather than evidence based medicine. Sleep, 2004, 27(8): 1441-1442.Mendelson WB. A review of the evidence for efficacy and safety of trazodone in insomnia. J Clin Psychiatry, 2005, 66(4): 469-476.Mendelson WB. A review of the evidence for efficacy and safety of trazodone in insomnia. J Clin Psychiatry, 2005, 66(4): 469-476.McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev, 2014, 3, CD009178.McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev, 2014, 3, CD009178.Smales ET, Edwards BA, Deyoung PN et al. Trazodone effects on obstructive sleep apnea and non-REM arousal threshold. Ann Am Thorac Soc, 2015, 12(5): 758-764.Smales ET, Edwards BA, Deyoung PN et al. Trazodone effects on obstructive sleep apnea and non-REM arousal threshold. Ann Am Thorac Soc, 2015, 12(5): 758-764.Zisapel N. Drugs for insomnia. Expert Opin Emerg Drugs, 2012, 17(3): 299-317.Zisapel N. Drugs for insomnia. Expert Opin Emerg Drugs, 2012, 17(3): 299-317.Yeung WF, Chung KF, Yung KP, Ng TH. Doxepin for insomnia: a systematic review of rand-omized placebo-controlled trials. Sleep Med Rev, 2015, 19: 75-83.Yeung WF, Chung KF, Yung KP, Ng TH. Doxepin for insomnia: a systematic review of rand-omized placebo-controlled trials. Sleep Med Rev, 2015, 19: 75-83.Winkler A, Auer C, Doering BK, Rief W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs, 2014, 28(9): 799-816.Winkler A, Auer C, Doering BK, Rief W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs, 2014, 28(9): 799-816.Griend JPV, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. J Am Pharm Assoc, 2012, 52(6): e210-e219.Griend JPV, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. J Am Pharm Assoc, 2012, 52(6): e210-e219.Michelson D, Snyder E, Paradis E et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, doubleblind, placebo-controlled trial. Lancet Neurol, 2014, 13(5): 461-471.Michelson D, Snyder E, Paradis E et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, doubleblind, placebo-controlled trial. Lancet Neurol, 2014, 13(5): 461-471.Herring WJ, Connor KM, Ivgy-May N et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry, 2016, 79(2): 136-148.Herring WJ, Connor KM, Ivgy-May N et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry, 2016, 79(2): 136-148.Monti J, Torterolo P, Pandi-Perumal SR. The effects of second generation antipsychotics in healthy subjects and patients with schizophrenia. Sleep Med Rev, 2017, 33: 51-57.Monti J, Torterolo P, Pandi-Perumal SR. The effects of second generation antipsychotics in healthy subjects and patients with schizophrenia. Sleep Med Rev, 2017, 33: 51-57.Thompson W, Quay TAW, Rojas-Fernandez C, Farrell B. Atypical antipsychotics for insomnia: a systematic review. Sleep Med, 2016, 22: 13-17.Thompson W, Quay TAW, Rojas-Fernandez C, Farrell B. Atypical antipsychotics for insomnia: a systematic review. Sleep Med, 2016, 22: 13-17.Schadeck SB, Chelly M, Amsellem D et al. Comparative efficacy of doxylamine (15 mg) and zolpidem (10 mg) for the treatment of common insomnia -- a placebo-controlled study. Sep Hop Pari, 1996, 72(13-14): 428-439.Schadeck SB, Chelly M, Amsellem D et al. Comparative efficacy of doxylamine (15 mg) and zolpidem (10 mg) for the treatment of common insomnia -- a placebo-controlled study. Sep Hop Pari, 1996, 72(13-14): 428-439.Ковальзон В. М., Стрыгин К. Н. Нейрохимические механизмы регуляции сна и бодрствования: роль блокаторов гистаминовых рецепторов в лечении инсомнии. Эффективная фармакотерапия, 2013, 12: 8-14.Kovalzon VM, Strygin KN. Neurochemical mechanisms of sleep-wake regulation: the role of histamine receptors blockers in the treatment of insomnia. Effective Pharmacotherapy, 2013, 12: 8-14.Бабак С.Л., Голубев Л.А., Горбунова М.В. Хроническая инсомния в клинической практике терапевта. РМЖ, 2008, 16(5): 259-266.Babak SL, Golubev LA, Gorbunova MV. Chronic insomnia in the clinical practice of the therapist. RMJ, 2008, 16 (5): 259-266.Адаменко Р.Я. Лечение инсомнии у больных хронической недостаточностью мозгового кровообращения. Журнал практического врача, 2001, 5: 45-51.Adamenko RYa. Treat ment of insomnia in patients with chronic cerebrovascular insufficiency. Zhurnal Prakticheskogo Vracha, 2001, 5: 45-51.Левин Я.И. Сон, инсомния, доксиламин (Донормил). РМЖ, 2007, 15(10): 850-855.Levin YaI. Sleep, insomnia, doxylamine (Donormil). RMJ, 2007, 15 (10): 850-855.Koren G. Safety considerations surrounding use of treatment options for nausea and vomiting in pregnancy. Expert Opin Drug Saf, 2017, 16(11): 1227-1234.Koren G. Safety considerations surrounding use of treatment options for nausea and vomiting in pregnancy. Expert Opin Drug Saf, 2017, 16(11): 1227-1234.American Geriatrics Society. Updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc, 2012, 60(4): 616-631.American Geriatrics Society. Updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc, 2012, 60(4): 616-631.Bent S, Padula A, Moore D, Patterson M et al. Valerian for sleep: a systematic review and meta-analysis. Am. J. Med., 2006, 119(12): 1005-1012.Bent S, Padula A, Moore D, Patterson M et al. Valerian for sleep: a systematic review and meta-analysis. Am. J. Med., 2006, 119(12): 1005-1012.Sateia MJ, Buysse DJ, Krystal AD et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med, 2017, 13(2): 307-349.Sateia MJ, Buysse DJ, Krystal AD et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med, 2017, 13(2): 307-349.Qaseem A, Kansagara D, Forciea MA et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 2016, 165(2): 125-133.Qaseem A, Kansagara D, Forciea MA et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 2016, 165(2): 125-133.

The authors declare that there are no conflicts of interest present.